aspsirna0700 details

''''
ASPsiRNA information siRNA Id:aspsirna0700
siRNA Name: G16
Mismatch information Wild siRNA (As strand 3'->5'):UCUAAACCUGGUCCGUCAG
ASP-siRNA (As strand 3'->5'):UCUGAACCUGGUCCGUCAG
Mismatch position in siRNA: G16A
Gene Information Gene Name Hungtintin (HTT)
Target Sequence (5'->3'):GCAAACCCUGACCGCAGUGCGGGGCAUUGG
Wild allele (5'->3'):AGAUUUGGACCAGGCAGUC
Mutant allele (5'->3'):AGACUUGGACCAGGCAGUC
Position of siRNA on target gene: NA
Respective Gene/Protein Resources GenBank Accession:NM_002111.7
Cytogenic location:4p16.3
Chromosomal coordinates:4:3,076,407-3,245,686
UniProt ID:Q96CV9
HUGO ID:4851
Reference SNp(RefSNP): rs19392295
Disease/Mutation information Target Mutation: c.52CAG(36_39)
Matation type/variant: Microsatellite
Mutation at gene level: NG_009378.1:g.5197CAG(36_39)
Pathogenic status of mutation: Pathogenic
Disease:Huntington disease (HD)
Clinical Resources ClinVar ID:31916
KEGG disease ID:H00059
OMIM ID: 143100
COSMIC: HTT
DECIPHER: HTT
GeneTests: HTT
ASP siRNA details Mutant allele (5'->3'): AGACUUGGACCAGGCAGUC
ASP-siRNA (As strand 3'->5'):UCUGAACCUGGUCCGUCAG
Percentage efficacy of ASP-siRNA for mutant allele:10
Wild allele (5'->3'): AGAUUUGGACCAGGCAGUC
ASP-siRNA (As strand 3'->5'):UCUGAACCUGGUCCGUCAG
Percentage efficacy of ASP-siRNA for wild allele:48
Relative difference:-38
Wild siRNA details Wild allele (5'->3'): AGAUUUGGACCAGGCAGUC
Wild siRNA (As strand 3'->5'):UCUAAACCUGGUCCGUCAG
Percentage efficacy of wild siRNA for wild allele:60
Wild allele (5'->3'): AGAUUUGGACCAGGCAGUC
ASP-siRNA (As strand 3'->5'):UCUGAACCUGGUCCGUCAG
Percentage efficacy of Wild sirna for mutant allele:15
Relative difference :45
General information Mismatch incorporated in siRNA/Target:siRNA
Cell-line used: Fibroblast
Experimental technique used: Western blot
Transfection method: Lipofectamine 2000
siRNA expression method: Metabion
Post-transfection duration: 72 hours
Concentration used:50nM
Reference:22397573
Delivery method:Transfection
Article title:An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases.
Authors:Fiszer A, Olejniczak M, Switonski PM, Wroblewska JP, Wisniewska-Kruk J, Mykowska A, Krzyzosiak WJ.
Journal Reference:BMC Mol Biol. 2012 Mar 7;13:6. doi: 10.1186/1471-2199-13-6.